Compositions and methods for improving cognitive function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceuticals targeting serotonin pathways for mood disorders have long onset times, severe side effects, and poor efficacy, posing risks to users, while psilocybin therapy is limited by adverse effects such as hallucinations and physical discomfort.
Innovation Solution
Development of low-dose pharmaceutical compositions containing 5HT receptor agonists like psilocin or psilocybin, administered in controlled release formulations to provide therapeutic effects without adverse side effects, with plasma concentrations below 6 ng/mL to minimize hallucinogenic experiences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of psilocybin are administered to achieve therapeutic effects on serotonin receptors, then treatment efficacy for mood disorders is improved, but adverse side effects such as hallucinations, panic attacks, and physical discomfort increase
Solution Approach 1:
The patent applies parameter changes by precisely controlling the dosage of psilocybin to fall within a specific therapeutic window (0.1-10 mg for adults). This dosage optimization resolves the contradiction by maintaining enough concentration to activate 5HT receptors for therapeutic effect while staying below the threshold that triggers adverse hallucinogenic effects. The patent also controls plasma concentration parameters to remain below 6 ng/mL to minimize side effects.
Solution Approach 2:
The patent employs partial action by administering a sub-maximal dose of psilocybin that is sufficient to achieve the desired therapeutic effect on serotonin receptors without exceeding the amount needed. This partial dosing strategy activates the necessary neural pathways for treating mood disorders while avoiding the excessive stimulation that causes hallucinations and panic attacks.
2Ease of manufacture
If conventional pharmaceuticals targeting serotonin pathways are used to treat mood disorders, then commercial availability and initial popularity are achieved, but onset times are prolonged and severe side effects occur
Solution Approach 1:
The patent extracts the active compound psilocybin from its natural mushroom source and formulates it as a purified pharmaceutical composition. This extraction allows for precise control over dosage and purity, enabling faster and more reliable onset of action compared to natural sources, while maintaining commercial manufacturability through standardized pharmaceutical production processes.
3Reliability
If psilocybin is administered to treat drug dependence and anxiety disorders, then therapeutic potential is realized, but physical discomfort such as nausea, vomiting, and muscle weakness occur
Solution Approach 1:
The patent controls the dosage parameter of psilocybin to remain within the therapeutic window that activates 5HT receptors for treating anxiety and drug dependence without reaching concentrations that cause physical discomfort. Additionally, the patent controls plasma concentration to stay below 6 ng/mL, which minimizes gastrointestinal and muscular side effects while preserving therapeutic benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively treat psychological and mood disorders with improved motivation, attention, and cognitive function, reducing the risk of adverse reactions and enhancing bioavailability and efficacy.
Implementation Method 1
The serotonin (5HT) receptors are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels found in the central and peripheral nervous systems. Activation of 5HT receptors can substantially influence brain function.
Implementation Method 2
The serotonin (5HT) receptors are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels found in the central and peripheral nervous systems.
Data Source
AI summary
Disclosed herein are methods for managing disorders or conditions, or treating symptoms of disorders or conditions, comprising administering 5HT receptor agonists. The disorders may involve cognitive function and the methods of improving may comprise administering low doses of 5HT receptor agonists to subjects in need thereof. Improvement of the symptoms of a disorder involving cognitive function can be achieved where the disorders comprise mood, cognitive, anxiety, and depression disorders. Also disclosed herein are pharmaceutical compositions, formulations, and dosage forms of 5HT receptor agonists.